US/UK/Canada

Share

Contacts

  • Cyxone AB
    Adelgatan 21 SE 211 22 Malmö
    +46 708882172
    +46 708882172
    http://www.cyxone.com

    • Quotes

    We are happy to announce the positive study outcomes, an instrumental part of the preparations for the Phase 2 study in RA patients set to start late next year. Equally, we are eagerly looking forward to the imminent initiation of our clinical study of Rabeximod in Covid-19 patients. Combined with the new patent applications recently filed, with potential to substantially prolong market exclusivity, and with a stockpile of drug substance enabling further clinical studies beyond those currently in the pipeline, we stand with a strong foothold in future partnering negotiations. All in all, Cyxone is well-positioned for the development of safe and innovative treatments toward serious immune system disorders.
    Tara Heitner, CEO, Cyxone
    After thorough evaluation, we were able to decide upon this CRO as our partner of choice for these preclinical studies. The selected CRO has an excellent reputation and we got a great impression of their quality and professionalism from the start. We now look forward to take the next step in the development program for our Phase II candidate Rabeximod.
    Malin Berthold, Head of Project Management at Cyxone
    This market maker is now being implemented to increase liquidity of our stock, which has sometimes been low. We look very favorably on this support measure, which is primarily done to benefit our shareholders through reduced trading risks.
    Kjell G. Stenberg, CEO of Cyxone
    The acquisition of Rabeximod is the most important milestone since Cyxone was founded. I have been following Rabeximod's development in OxyPharma for a long time and believe that this investment is very beneficial for our shareholders. We have in a short time been able to build a world-class autoimmune product portfolio, which has permeated the discussions we have had with different stakeholders regarding the financing of Rabeximod's phase IIb study. This is why we are now taking the opportunity to complete the payment and hope to return soon to our shareholders with more positive news regarding Rabeximod.
    Kjell G. Stenberg, CEO of Cyxone
    Pick a time period -

    Cyxone takes next step in Multiple Sclerosis program engaging Contract Development & Manufacturing Organization for production of T20K

    Cyxone (publ) announces today that the company has engaged a renowned European Contract Development & Manufacturing Organization (CDMO) for the scale-up and production of the active ingredient of its drug candidate T20K. The production will be performed in accordance with Good Manufacturing Practice (GMP), exploring a brand-new manufacturing method. The collaboration will initially cover method development and later supply material for use in non-clinical and clinical development activities.Cyxone is developing T20K, a peptide aimed for the treatment of multiple sclerosis (MS). Preclinical

    Cyxone step up activities and extend collaboration with global CRO around RA trial

    Cyxone (publ) announces today that the company has signed a Letter of Agreement (LOA) with the internationally renowned clinical contract research organization (CRO) following on an early operations agreement (EOA) signed last month. The LOA is a key step for advancing the clinical phase 2b trial of Rabeximod in patients with rheumatoid arthritisThe agreement enables Cyxone to expand and intensify start-up activities for the phase 2b trial including site selections and regulatory submissions enabling an efficient route to enrolling patients into the trial within the shortest period of time.

    Cyxone publishes prospectus due to the upcoming rights issue

    NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE.The board of directors of Cyxone AB (“Cyxone” or the “Company”) has, in connection with the Company's upcoming rights issue that was announced on 21 December 2021 (the “Rights Issue”), prepared an EU Growth Prospectus (the “Prospectus”), which

    Cyxone executes a rights issue of SEK 66.9 million secured to 91 % ahead of the Phase 2b study in RA

    NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE.The board of directors of Cyxone AB ("Cyxone" or the “Company") has today, pursuant to the authorization granted by the Annual General Meeting on 3 June 2021, resolved to carry out a rights issue of shares with preferential rights for the Company'

    BioStock: Cyxone CRO agreement signals Phase IIb RA trial moving forward as planned

    In the preparation for the coming phase IIb trial with Rabeximod in rheumatoid arthritis, biotech company Cyxone has entered an Early Operations Agreement with an internationally renowned clinical contract research organisation. BioStock contacted CEO Tara Heitner to learn more.Read the interview with Cyxone's CEO Tara Heitner at biostock.se: https://www.biostock.se/en/2021/12/cyxones-cro-agreement-signal-phase-iib-ra-trial-is-moving-forward-as-planned/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

    Cyxone reports publication of four patent applications pertaining to its drug candidate Rabeximod

    Cyxone (publ) today announces that four patent applications pertaining to its drug candidate Rabeximod have been published by the PCT authority (WIPO). If approved, these patents have potential to prolong the market exclusivity of Rabeximod until 2041.The four patent applications published by the PCT authority (WIPO) are: [A] PCT/EP2021/065705 New Oral Formulation (this patent if granted is expected to give good protection for oral formulation of Rabeximod in crystalline form) [B] PCT/EP2021/065693 New Use of Rabeximod (this patent if granted is expected to give good protection for

    Cyxone initiates early operations with a global contract research organization to conduct Phase 2b trial in rheumatoid arthritis

    Cyxone (publ) announces today that the company has initiated an early operations agreement (EOA) with an internationally renowned contract research organization (CRO) to prepare for the upcoming clinical Phase 2b trial of Rabeximod in patients with rheumatoid arthritis. As part of the EOA, the CRO will support Cyxone in start-up and feasibility activities including finalization of the trial protocol and selection of the countries and trial sites that meet the criteria of the trial design.Cyxone is developing Rabeximod, an oral potential first line treatment for patients suffering from the

    Cyxone files patent application with potential to extend market exclusivity of the drug candidate Rabeximod

    Cyxone (publ) today announces that the company has filed a new patent application for Rabeximod with patent authorities in key strategic territories. Approval of this new patent application on these markets, in conjunction with four additional patents filed during the period 2020–2021, will strengthen the intellectual property portfolio for Rabeximod and elongate the market exclusivity period until at least 2043.Rabeximod is a well-tolerated, orally available Phase 2 drug candidate that selectively targets the inflammatory macrophage – the central orchestrator of the inflammatory process.

    BioStock Studio: Cyxone comments on the Covid-19 study results

    Biotech company Cyxone has announced results from their phase II trial with drug candidate Rabeximod in patients with moderate to severe Covid-19. The data were inconclusive in terms of the effect of the drug candidate compared to standard of care treatment and Cyxone will now analyse the results further. In parallel, the company is preparing Rabeximod for a coming phase II trial in rheumatoid arthritis, the main focus for the candidate and Cyxone’s leading project. Tara Heitner, CEO, and Carl-Magnus Högerkorp, COO, visited the BioStock Studio to explain.Watch the interview with Cyxone at

    Cyxone presents top-line results from a phase 2 study of Rabeximod in Covid-19 patients

    Cyxone (publ) today announces top-line results from a phase 2 study of Rabeximod in Covid-19 patients with moderate disease. The primary endpoint, ultimately proposed by the FDA, was to document the difference of the proportion of subjects alive and free of respiratory failure at day 28 between placebo (standard of care treatment) and Rabeximod plus standard of care. The topline data analysis showed that almost all patients were alive and free of respiratory failure at day 28 in the different treatment arms. No statistical difference between treatment arms could be observed at day 28, thus

    Cyxone announces change of Certified Adviser to FNCA

    Cyxone AB (publ), Reg. No. 559020-5471 (the ”Company”), hereby announces that the Company has entered into an agreement with FNCA Sweden AB (”FNCA”) regarding the service as a Certified Adviser. FNCA will be appointed Certified Adviser (CA) on 1 December 2021. Up until then, Mangold Fondkommission AB will continue to act as Certified Adviser for the Company.Contact Tara Heitner, CEOTel: +46 (0)70 781 88 08Email: tara.heitner@cyxone.com The information was submitted for publication, through the agency of the contact person set out above, at 14.15 p.m. CET on 30 November 2021.

    BioStock: Pre-clinical data indicates wider use for Cyxone’s T20K in MS

    Biotech company Cyxone is developing T20K, a drug candidate with first-in-class potential for the treatment of multiple sclerosis. Recently, Cyxone’s research partner, the Medical University of Vienna, presented pre-clinical data supporting T20K as a treatment for MS in combination with a kappa opioid receptor agonist, the combination having potential expanded therapeutic utility. BioStock reached out to COO Carl-Magnus Högerkorp for a comment.Read the interview with Cyxone's COO Carl-Magnus Högerkorp at biostock.se: https://www.biostock.se/en/2021/11/pre-clinical-data-indicates-wider-

    Cyxone announces promising preclinical results supporting T20K combination therapy for multiple sclerosis

    Cyxone (publ) announces today that the company, together with its academic partner Medical University of Vienna, has continued to investigate the drug candidate T20K in combination with a kappa opioid receptor agonist. A combination which in pre-clinical experiments demonstrate promising synergistic therapeutic effects and potential disease modifying features in multiple sclerosis. The results build upon previous data which underpin a patent application to the European Patent Office that recently was made public.Multiple sclerosis (MS) is a chronic autoimmune disease that emerges when the

    Cyxone will leverage IND and use FDA pre-review for Covid-19 phase 2 trial

    Cyxone AB (publ) announces today that the company is expecting to communicate top-line results from a recently concluded Phase 2 trial of its drug candidate Rabeximod in Covid-19 patients during the fourth quarter. The results were previously slated for the third quarter. The postponement is due to the company’s decision to leverage the U.S. Food and Drug Administration (FDA) initiative to pre-review the statistical analysis plan for the clinical trial, whereby the exact timing of the results will depend on the process and discussion required with the FDA. This is an extraordinary opportunity

    Cyxone appoints Cornel Pater as new Chief Medical Officer

    Cyxone today announced that Cornel Pater has been appointed as the company’s new Chief Medical Officer (CMO). Most recently, he held the position as Global Medical Director of Clinical Development at Novartis Pharma. As CMO, Cornel Pater is part of Cyxone’s executive management and will play an important role in the continued development of the company’s projects. He joined the company on August 31, 2021.“I am glad to welcome Cornel Pater to Cyxone. As Chief Medical Officer, his comprehensive knowledge and experience from leading pharmaceutical development projects and coordinating global

    Interim Report 1 January to 30 June 2021

    Financial Summary for the groupKSEK Q2 Q2 Q1-Q2 Q1-Q2 2021 2020 2021 2020Profit/loss before tax -11 458 -14 197 -20 069 -24 394Total assets 69 240 58 357 69 240 58 357Earnings per share before -0,19 -0,29 -0,34 -0,50and after dilution (SEK)Cash and cash equivalents 54 054 41 611 54 054 41 611as per period endEquity ratio as per 92,6% 89,3% 92,6% 89,3%period end Significant events during the second quarter of 2021 · World leading

    Cyxone recruits key members to the clinical development team

    Cyxone today announced that the company has recruited Anna Polak and Levente Dajka as members of the Cyxone development team. Both will bring vast knowledge in clinical trial management, their initial focus will fall primarily on the preparations for the planned phase 2 trial investigating the clinical effect of Rabeximod in rheumatoid arthritis, set to start during 2021.Anna Polak holds a degree in pharmacy from the Medical University of Warsaw and has 15 years of global trial management experience in contract research organizations (CROs), ranging from initial protocol design to final

    BioStock: Cyxone has closed recruitment to the phase II Covid-19 trial

    Swedish biotech Cyxone announced last month that the patient recruitment for its phase II trial testing Rabeximod in Covid-19 could come to a close as a sufficient number of patients have been enrolled to power an effective analysis. BioStock reached out to Cyxone’s CEO Tara Heitner to get her thoughts on the implications of the news.Read the full interview with CEO Tara Heitner at biostock.se: https://www.biostock.se/en/cyxone-has-closed-recruitment-to-the-phase-ii-covid-19-trial/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

    BioStock: Cyxone is exploring new treatment possibilities for T20K

    After identifying new therapeutic treatment possibilities for T20K, Cyxone has announced a research collaboration with the Medical University of Vienna to further validate these findings and to deepen the understanding of T20K’s mode of action. The aim of the project is to prepare for a clinical phase I study with the new administration form. BioStock reached out to COO Carl-Magnus Högerkorp and Non-Clinical Project Manager Sally Abdelmoaty for a comment.Read the full interview at biostock.se: https://www.biostock.se/en/cyxone-is-exploring-new-treatment-possibilities-for-t20k/ This is

    Cyxone announces Rabeximod in Covid-19 Phase 2 trial closed, data to be reported in Q3

    Cyxone today announced that the Rabeximod in Covid-19 trial that has been conducted in Eastern Europe during Q1-Q2 2021 will be closed as the trial has been shown to have a sufficient number of patients enrolled to allow for statistical analysis.Recently Cyxone reported that patient recruitment for the clinical study conducted in Covid-19 patients in Eastern Europe was challenged as Covid-19 cases declined and a study delay was predicted. Approximately 90 patients have been enrolled into the trial to date, and after reanalysis of the statistical requirements for study size it has been

    Cyxone and Medical University of Vienna announce collaboration to study broader T20K use in MS

    After identifying some valuable new potential treatments for T20K, Cyxone AB (publ) (“Cyxone or the Company”) today announced that the company has entered into a research collaboration with Prof. Christian Gruber, the inventor of T20K & Prof. Gernot Schabbauer from the Medical University of Vienna. The aim of the study is to deepen the understanding of the mode of action (MoA) of T20K and to explore these new uses and the potential to provide significant additional therapeutic benefit in a model for multiple sclerosis. The study will start later this month, with planned readout in June 2022,

    Cyxone explores expanding into new regions to mitigate potential delay in Covid-19 trial completion

    Cyxone initiated a clinical trial in Eastern Europe with Rabeximod as a treatment for patients with moderate Covid-19 in January 2021. Approximately 90 patients have been successfully enrolled to date. With the declining number of hospitalized Covid-19 patients in Eastern Europe, Cyxone is now considering opening up trial sites in more countries and has had to push back the projected study readout later than Q3 2021.After discovering that the rheumatoid arthritis drug candidate Rabeximod, could be effective in patients with moderate Covid-19, Cyxone started a Phase 2 clinical trial in

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe

    Media